World's Best Scientists 2026 revealed!
Award Badge
Best Female Scientists
2025

D-Index & Metrics

Best Female Scientists

D-Index
157
Citations
95467
World Ranking
113
National Ranking
64

Medicine

D-Index
161
Citations
103085
World Ranking
747
National Ranking
425

Research.com Recognitions

  • 2025 - Research.com Best Female Scientists Award

Overview

Razelle Kurzrock is affiliated with the Medical College of Wisconsin in the United States. Their research primarily focuses on oncology within the broader fields of medicine and biochemistry, genetics, and molecular biology. They have contributed extensively to subfields such as oncology, cancer research, pulmonary and respiratory medicine, molecular biology, and pathology and forensic medicine.

Their scientific work covers several main topics, including cancer genomics and diagnostics, cancer immunotherapy and biomarkers, lung cancer treatments and mutations, pancreatic and hepatic oncology research, colorectal cancer treatments and studies, genetic factors in colorectal cancer, and CAR-T cell therapy research.

Razelle Kurzrock has authored numerous papers published in frequent venues such as Journal of Clinical Oncology, Annals of Oncology, Clinical Cancer Research, Cancer Research, and The Oncologist. Their research collaboration network includes frequent coauthors like Shumei Kato, Jacob J. Adashek, Jason K. Sicklick, Ryosuke Okamura, and Suzanna Lee.

Recent publications by Razelle Kurzrock include:

  • The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker, 2020, Cancer Cell
  • Liquid biopsy: current technology and clinical applications, 2022, Journal of Hematology & Oncology
  • Review of precision cancer medicine: Evolution of the treatment paradigm, 2020, Cancer Treatment Reviews
  • Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study, 2021, The Lancet Oncology
  • A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors, 2020, Clinical Cancer Research

Best Publications

  • PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

    Sandip Pravin Patel;Razelle Kurzrock

  • Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.

    Aaron M. Goodman;Shumei Kato;Lyudmila Bazhenova;Sandip P. Patel

  • The biology of chronic myeloid leukemia

    Stefan Faderl;Moshe Talpaz;Zeev Estrov;Susan O'Brien

  • Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer

    Navneet Dhillon;Bharat B. Aggarwal;Robert A. Newman;Robert A. Wolff

  • The Molecular Genetics of Philadelphia Chromosome–Positive Leukemias

    Razelle Kurzrock;Jordan U. Gutterman;Moshe Talpaz

  • Epstein-Barr Virus and Cancer

    Matthew P. Thompson;Razelle Kurzrock

  • Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

    Gerald S Falchook;Georgina V Long;Georgina V Long;Razelle Kurzrock;Kevin B Kim

  • Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors

    Nithya Krishnamurthy;Razelle Kurzrock

  • Autophagy as a target for anticancer therapy

    Filip Janku;David J. McConkey;David S. Hong;Razelle Kurzrock

  • Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate

    Shumei Kato;Aaron Michael Goodman;Vighnesh Walavalkar;Donald A. Barkauskas

  • The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing

    Teresa Helsten;Sheryl Elkin;Elisa Arthur;Brett N. Tomson

  • The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker.

    Denis L. Jardim;Aaron Goodman;Debora de Melo Gagliato;Razelle Kurzrock

  • Clinical toxicity of interferons in cancer patients: a review.

    Jorge R. Quesada;Moshe Talpaz;Adan Rios;Razelle Kurzrock

  • Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study

    Jason K. Sicklick;Shumei Kato;Ryosuke Okamura;Maria Schwaederle

  • Chronic myelogenous leukemia: a concise update

    H. M. Kantarjian;A. Deisseroth;R. Kurzrock;Z. Estrov

  • Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer

    Razelle Kurzrock;Steven I. Sherman;Douglas W. Ball;Arlene A. Forastiere

  • Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.

    Gerald S Falchook;Karl D Lewis;Jeffrey R Infante;Michael S Gordon

  • Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

    Jeffrey R. Infante;Leslie A. Fecher;Gerald S. Falchook;Sujatha Nallapareddy

  • Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative

    Apostolia M. Tsimberidou;Nancy G. Iskander;David S. Hong;Jennifer J. Wheler

  • Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer

    Roy S. Herbst;S. Gail Eckhardt;Razelle Kurzrock;Scot Ebbinghaus

Frequent Co-Authors

David S. Hong
David S. Hong The University of Texas MD Anderson Cancer Center
Filip Janku
Filip Janku The University of Texas MD Anderson Cancer Center
Apostolia Maria Tsimberidou
Apostolia Maria Tsimberidou The University of Texas MD Anderson Cancer Center
Sarina Anne Piha-Paul
Sarina Anne Piha-Paul The University of Texas MD Anderson Cancer Center
Moshe Talpaz
Moshe Talpaz University of Michigan–Ann Arbor
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam
Funda Meric-Bernstam The University of Texas MD Anderson Cancer Center
Jordan U. Gutterman
Jordan U. Gutterman The University of Texas MD Anderson Cancer Center
Zeev Estrov
Zeev Estrov The University of Texas MD Anderson Cancer Center
Kenneth R. Hess
Kenneth R. Hess The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medicine in the USA opens doors to numerous healthcare careers beyond becoming a physician. With flexible online study options, you can fast-track your path or specialize in high-demand fields. For those looking to lead in healthcare, pursuing one of the best online healthcare administration degree programs can lead to management roles in hospitals and clinics.

If you’re a registered nurse aiming to advance your skills, consider rn to np programs. These bridge programs allow RNs to become nurse practitioners with greater autonomy and earning potential. For those interested in preventive healthcare and wellness, earning an online degree in nutrition prepares you for rewarding roles in clinical or community settings.

To stand out in healthcare leadership, choose from the top online mha programs that are cahme accredited. Accreditation ensures high educational standards and enhances job market credibility. No matter your interests, online degree pathways offer flexibility and specialization, helping you build a strong foundation for a diverse healthcare career.

Best Scientists Citing Razelle Kurzrock

Trending Scientists

Recently Published Articles